Search
Medicaid Monitor
Thursday, October 8, 2026 · Updated 12:07 PM MT · 47 stories today
Daily Briefing · 47 stories todayPRO

The complete record

9 stories, Friday, June 26, 2026

Federal Policy

3 storiesFederal Policy section →

House Hearing Surfaces Partisan Split on CMS Medicaid Funding Deferrals

A House subcommittee hearing Thursday revealed sharp partisan divides over recent CMS actions deferring or threatening Medicaid funding in multiple states. State Medicaid directors defended program integrity efforts while Democratic members questioned why only Democratic-led states have faced funding actions despite administration claims the crackdown applies nationwide. The hearing focused on CMS's authority to withhold federal matching funds and the criteria used to identify states for enhanced scrutiny. The dispute centers on whether recent enforcement actions reflect objective program integrity standards or politically motivated targeting.

Why it mattersMCOs in states facing CMS funding actions may see delayed capitation payments, contract amendments, or heightened state-level audits as states respond to federal scrutiny of enrollment and eligibility processes.

USHealthcare Dive1:30 PM MT
Managed Care · Finance

MACPAC Releases 2026-2027 Meeting Agenda on Program Integrity and Federal Oversight

The Medicaid and CHIP Payment and Access Commission (MACPAC) has published its analytic agenda for the 2026-2027 meeting cycle. The agenda includes program integrity, the federal role in Medicaid oversight, and other policy areas that will be examined through public meetings and research over the next two years. MACPAC's work typically informs congressional deliberations and CMS policy development. Managed care organizations should monitor MACPAC proceedings as the Commission's recommendations often lead to regulatory or legislative changes affecting MCO operations, compliance requirements, and payment policy.

Why it mattersMACPAC's research agenda signals future federal policy directions that may result in new managed care requirements, program integrity standards, or oversight mechanisms affecting MCO contracts and operations.

USMACPAC1:30 PM MT
Managed Care · Finance

CMS Prioritizes IRA Implementation and PBM Reform in Drug Pricing Agenda

The Trump administration has placed drug pricing at the top of its health policy agenda, with CMS focusing on implementing Inflation Reduction Act provisions and pursuing pharmacy benefit manager reforms. The agency is working on Medicare price negotiation, inflation rebates, and Part D redesign while exploring PBM transparency and reform measures. These initiatives affect how Medicaid managed care organizations negotiate drug prices, manage pharmacy benefits, and coordinate with Medicare for dual-eligible beneficiaries. The timeline for specific regulatory actions remains under development.

Why it mattersMedicaid MCOs must align pharmacy benefit management strategies with evolving federal drug pricing rules, particularly for dual-eligible populations where Medicare and Medicaid coverage intersect.

USjdsupra.com7:30 AM MT
Pharmacy · Managed Care · Finance

State Policy

2 storiesState Policy section →

Young Children's Uninsurance Rises Faster Than School-Age Peers Pre-2025

Analysis shows young children experienced faster uninsurance growth compared to school-aged children prior to 2025 Medicaid enrollment declines. The trend emerged before recent federal policy changes including Trump administration actions and H.R. 1 proposals. The data suggests underlying coverage gaps for young children independent of current redeterminations. States may need targeted outreach and enrollment strategies for families with young children to reverse the trend.

Why it mattersMedicaid managed care organizations serving pediatric populations should examine age-specific enrollment patterns and retention strategies, as coverage gaps among young children may signal downstream membership volatility and HEDIS performance risks.

USGeorgetown CCF1:30 PM MT
CHIP · Managed Care

Connecticut Medicaid Spending Rose in 2024 but Remained Lowest Per-Member Cost

Connecticut's Medicaid program experienced spending increases in 2024 while maintaining the lowest per-enrollee costs compared to commercial insurance markets in the state. The data shows Medicaid's cost efficiency persisted despite upward spending pressure. The comparison encompasses all insurance market segments operating in Connecticut. Medicaid managed care organizations in the state continue to deliver care at lower per-member costs than commercial carriers, though absolute spending grew year-over-year.

Why it mattersConnecticut MCOs maintained cost efficiency advantages over commercial plans despite spending growth, providing a benchmark for rate negotiations and demonstrating managed care's ability to control per-member costs relative to other coverage models.

CTctmirror.org1:30 PM MT
Managed Care · Finance

Industry

2 storiesIndustry section →

Proposed Legislation Would Restructure Federal 340B Drug Pricing Program

Congressional legislation has been introduced to overhaul the 340B drug discount program, which requires pharmaceutical manufacturers to provide discounted outpatient drugs to eligible healthcare providers. The bill would restructure eligibility requirements and oversight mechanisms for the program that currently serves safety-net providers including some Medicaid managed care organizations and federally qualified health centers. If enacted, the changes would affect how covered entities access discounted medications and could alter prescription drug cost structures for Medicaid plans contracting with 340B-eligible providers. The proposal comes amid ongoing disputes between manufacturers and covered entities over contract pharmacy arrangements and duplicate discount prohibitions.

Why it mattersChanges to 340B eligibility and oversight could affect Medicaid MCO pharmacy costs and duplicate discount compliance obligations when members receive care at 340B-covered entities.

USSTAT News1:30 PM MT
Pharmacy · Managed Care

Jails Face Medetomidine-Laced Opioid Withdrawal Crisis Without Treatment Protocols

Correctional facilities are increasingly encountering severe withdrawal cases from opioids contaminated with medetomidine, a veterinary sedative, but lack established treatment protocols for this emerging threat. The drug causes life-threatening withdrawal symptoms distinct from traditional opioid withdrawal, including extreme cardiovascular instability. Jails serve as unintentional frontline medical facilities as individuals enter custody experiencing these dangerous withdrawal episodes. Many facilities remain unprepared with limited access to specialized medical staff or evidence-based treatment approaches for this substance combination.

Why it mattersMedicaid managed care organizations will face coverage and care coordination obligations for justice-involved individuals experiencing medetomidine-complicated withdrawal upon community reentry, requiring protocols for addressing non-standard substance use disorders and potential high-acuity medical needs.

USSTAT News7:31 AM MT
Behavioral Health · Managed Care

Get the daily briefing.